FDA Approves Regeneron's Otarmeni as First Gene Therapy for Genetic Hearing Loss, with the Drugmaker Pledging Free Access in the U.S.
Regeneron's one-time intracochlear gene therapy for OTOF-related deafness cleared the FDA 61 days after BLA filing, the first gene therapy product approved under the Commissioner's National Priority Voucher pilot program.
5 min read4 sources